echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The driving effect of MET expansion on some non-small cell lung cancer

    The driving effect of MET expansion on some non-small cell lung cancer

    • Last Update: 2021-07-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Camidge said that many major advances in the treatment of non-small cell lung cancer have come from the molecular specific subgroups that define the disease, and researchers have been able to develop targeted treatments


    "We are beginning to realize that non-small cell lung cancer is not a disease," Camidge said


    Gene amplification is a driver of cancer

    This new paper titled "Crizotinib in met-amplified NSCLC patients" was published in the June issue of the Journal of Thoracic Oncology and introduced a third method for defining NSCLC subgroups.


    "Unlike gene mutations or gene rearrangements-either present or not-gene amplification is a constant variable," Camidge said


    In this study, Camidge and other researchers focused specifically on MET amplification in a Pfizer-sponsored study


    If MET expansion is a cancer driver in some patients, it makes sense that inhibiting MET can slow or stop the progression of NSCLC in these patients


    To verify this theory, the study requires hospitals and cancer centers to use a genetic test called fluorescence in situ hybridization (FISH) to perform MET amplification on tumor samples from patients with non-small cell lung cancer


    During the study period, a total of 88 patients with different levels of MET amplification received crizotinib


    The results showed that patients with the highest level of MET amplification had the highest response rate to crizotinib treatment and experienced a longer survival period without tumor progression, while patients with lower levels of MET amplification had a poorer response to treatment


    This study, which began in 2006, is one of the biggest efforts to determine relevant diagnostic tests for meaningful levels of MET gene amplification and to prove that MET inhibitor drugs are effective in treating NSCLC patients driven by MET amplification


    Camidge said: "For this rare subtype of lung cancer, this is a long and difficult process, but I think this is quite good evidence that some patients just MET amplification caused their cancer


    For seeing amplification testing and treatment

    Camidge said there are many reasons why non-small cell lung cancer driven by MET expansion is unique


    Second, it often occurs in lung cancer patients who are not usually identified as having carcinogenic factors, including smokers and the elderly


    "This is not your classic driver oncogene subtype," he said


    Because of this, Camidge said, patients with non-small cell lung cancer who have not been identified as driving oncogenes should consider MET amplification testing


    Camidge said: "Although some sequencing tests can be compared with FISH tests and reliably detect gene amplification, others cannot


    When using inhibitors to treat patients with amplification-driven NSCLC, Camidge said that pharmaceutical companies began to explore satisfaction amplification as additional new and existing target satisfaction inhibitors, and he hopes that the team’s findings will help inform R&D and ultimately help patients.

    .

    "This is a truly operable oncogene," he said
    .
    "It's rare, but it's true
    .
    "

    Journal Reference :

    1. D.
      Ross Camidge et al.
      Crizotinib in Patients With MET-Amplified NSCLC .
      Journal of Thoracic Oncology , 2021 DOI: 10.
      1016/j.
      jtho.
      2021.
      02.
      010


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.